Reviewing Cerecor Inc. (CERC)’s and Cue Biopharma Inc. (NASDAQ:CUE)’s results

Both Cerecor Inc. (NASDAQ:CERC) and Cue Biopharma Inc. (NASDAQ:CUE) are Biotechnology companies, competing one another. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerecor Inc. 3 0.00 18.36M -1.25 0.00
Cue Biopharma Inc. 9 0.00 17.57M -2.11 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 represents Cerecor Inc. (NASDAQ:CERC) and Cue Biopharma Inc. (NASDAQ:CUE)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Cerecor Inc. 547,226,610.24% -218.9% -65.9%
Cue Biopharma Inc. 194,143,646.41% 0% 0%

Liquidity

The Current Ratio of Cerecor Inc. is 1 while its Quick Ratio stands at 0.9. The Current Ratio of rival Cue Biopharma Inc. is 3 and its Quick Ratio is has 3. Cue Biopharma Inc. is better equipped to clear short and long-term obligations than Cerecor Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Cerecor Inc. and Cue Biopharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerecor Inc. 0 0 1 3.00
Cue Biopharma Inc. 0 0 0 0.00

Cerecor Inc. has a 224.32% upside potential and a consensus target price of $12.

Insider and Institutional Ownership

Roughly 55.2% of Cerecor Inc. shares are owned by institutional investors while 21.7% of Cue Biopharma Inc. are owned by institutional investors. Insiders owned 1.2% of Cerecor Inc. shares. Competitively, insiders own roughly 0.4% of Cue Biopharma Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerecor Inc. -9.84% -28.67% -24.11% -22.2% -8.41% 24.77%
Cue Biopharma Inc. 19.74% -6.1% 3.36% 65.54% -11.97% 76.81%

For the past year Cerecor Inc. was less bullish than Cue Biopharma Inc.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company's biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.